TABLE 2

Side Effects in Patients with GEP Tumors and Treated with Various Radiolabeled Somatostatin Analogs

Center (reference)	Ligand	No. of patients	Toxicity
						Grade 3 or 4 hematologic*			Other^†
						Platelets	Hb	WBC	Other^†
Rotterdam (2)	[¹¹¹In-DTPA⁰]octreotide	50	10	15	2	3 AML or MDS
New Orleans (3)	[¹¹¹In-DTPA⁰]octreotide	27	7	11	7	3 liver, 1 renal
Milan (10)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	40	7	3	7
Basel (4)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	29	3	7	0	4 renal^‡
Basel (6)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	39	0	3	0	1 renal
Rotterdam (11)	[⁹⁰Y-DOTA⁰, Tyr³]octreotide	60	12	8	13	1 MDS, 1 liver, 1 renal
Rotterdam (18)	[¹⁷⁷Lu-DOTA⁰, Tyr³]octreotate	200	3	1	2	1 MDS, 1 renal

↵* Reported as percentage of patients. Hb = hemoglobin; WBC = white blood cells.
↵^† Reported as number of patients with indicated type of toxicity. AML = acute myeloid leukemia.
↵^‡ No amino acid infusion in half of patients.